{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-298718","form_type":"8-K","ticker":"GH","cik":"0001576280","company_name":"Guardant Health, Inc.","filed_at":"2023-12-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.602363+00:00","generated_at":"2026-06-07T10:33:33.348850+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Guardant Health announces March 28, 2024 FDA panel review date for Shield colorectal cancer blood test","bullets":["FDA's Molecular and Clinical Genetics Panel tentatively set to review Shield PMA on March 28, 2024, subject to confirmation.","Shield blood test data derived from ECLIPSE study of over 20,000 average-risk adults for colorectal cancer detection.","Co-CEO AmirAli Talasaz states proposed timing aligns with completing PMA process and launching Shield IVD in 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-298718","json":"https://secwatch.observer/filing/0001193125-23-298718.json","markdown":"https://secwatch.observer/filing/0001193125-23-298718.md","text":"https://secwatch.observer/filing/0001193125-23-298718.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1576280/000119312523298718/0001193125-23-298718-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1576280/000119312523298718/d719875d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T10:33:33.348850+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}